Non-Small Cell Lung Carcinoma TNM clinical staging
Item
1. participants with histologically or cytologically confirmed stage iii non-small cell lung cancer (nsclc).
boolean
C0007131 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
Measurable Disease
Item
2. participants in the randomized portion of the study must have measurable disease per response evaluation criteria in solid tumors (recist), version 1.1 criteria.
boolean
C1513041 (UMLS CUI [1])
Tumor Volume | Lung Volume Measurement Suitable Therapeutic radiology procedure
Item
3. participants must have tumor volume of ≤ 150 cm^3 and v20 (volume of lung to receive 20 gy radiotherapy according to simulation) < 35%.
boolean
C0475276 (UMLS CUI [1])
C0024129 (UMLS CUI [2,1])
C3900053 (UMLS CUI [2,2])
C1522449 (UMLS CUI [2,3])
ECOG performance status
Item
4. participant must have an eastern cooperative oncology group (ecog) performance score of 0 - 1.
boolean
C1520224 (UMLS CUI [1])
Hematologic function | Renal function | Liver function | Pulmonary function
Item
5. participant must have adequate hematologic, renal, hepatic, and lung function.
boolean
C0221130 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
C0232741 (UMLS CUI [3])
C0231921 (UMLS CUI [4])
Prior Chemotherapy Non-Small Cell Lung Carcinoma | Prior radiation therapy Non-Small Cell Lung Carcinoma
Item
1. participants with prior chemotherapy or radiotherapy (rt) for current nsclc. participants curatively treated for past early stage nsclc greater than 3 years ago may be included.
boolean
C1514457 (UMLS CUI [1,1])
C0007131 (UMLS CUI [1,2])
C0279134 (UMLS CUI [2,1])
C0007131 (UMLS CUI [2,2])
Exposure to Poly(ADP-ribose) Polymerase Inhibitors
Item
2. participants with prior exposure to poly-adp-ribose polymerase (parp) inhibitors.
boolean
C0332157 (UMLS CUI [1,1])
C1882413 (UMLS CUI [1,2])
Carboplatin allergy | Paclitaxel allergy | Hypersensitivity POLYOXYETHYLATED CASTOR OIL | Hypersensitivity Cremophor
Item
3. participants with known hypersensitivity to carboplatin, paclitaxel, or formulations containing polyethoxylated castor oil (cremophor).
boolean
C0570701 (UMLS CUI [1])
C0570707 (UMLS CUI [2])
C0020517 (UMLS CUI [3,1])
C0982061 (UMLS CUI [3,2])
C0020517 (UMLS CUI [4,1])
C0056475 (UMLS CUI [4,2])
Radiotherapy to mediastinum | Radiotherapy to thorax
Item
4. participants with prior mediastinal or thoracic radiotherapy. prior tangential rt to prior breast cancer is acceptable.
boolean
C4049191 (UMLS CUI [1])
C4038705 (UMLS CUI [2])
Major surgery | Exception Video-Assisted Thoracic Surgery | Exception Mediastinoscopy
Item
5. participants with major surgery in the 4 weeks prior to randomization (video-assisted thoracoscopic surgery (vats) and/or mediastinoscopy is not considered major surgery).
boolean
C0679637 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0752151 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0025065 (UMLS CUI [3,2])
Cancer Other | Exception Basal cell carcinoma Treated | Exception Squamous cell carcinoma of skin Treated | Exception Carcinoma in situ of uterine cervix Treated | Exception Curative treatment Cancer Other | Exception Disease Free Duration | Exception Patient Cured
Item
6. participants with a previous or concurrent malignancy except for treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient received potentially curative treatment and has been disease-free for 3 years or is considered cured by the investigator if has been disease-free for less than 3 years.
boolean
C1707251 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0007117 (UMLS CUI [2,2])
C1522326 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0553723 (UMLS CUI [3,2])
C1522326 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C0851140 (UMLS CUI [4,2])
C1522326 (UMLS CUI [4,3])
C1705847 (UMLS CUI [5,1])
C1273390 (UMLS CUI [5,2])
C1707251 (UMLS CUI [5,3])
C1705847 (UMLS CUI [6,1])
C0012634 (UMLS CUI [6,2])
C0332296 (UMLS CUI [6,3])
C0449238 (UMLS CUI [6,4])
C1705847 (UMLS CUI [7,1])
C0030705 (UMLS CUI [7,2])
C1880198 (UMLS CUI [7,3])
Pregnancy | Breast Feeding
Item
7. participant is pregnant or lactating.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Peripheral sensory neuropathy CTCAE Grades | Lacking Able to swallow Pharmaceutical Preparations | Seizure
Item
8. participant with sensory peripheral neuropathy of ≥ grade 2 at baseline, unable to swallow medication, or participants with prior history of seizure within the prior 12 months.
boolean
C0151313 (UMLS CUI [1,1])
C1516728 (UMLS CUI [1,2])
C0332268 (UMLS CUI [2,1])
C2712086 (UMLS CUI [2,2])
C0013227 (UMLS CUI [2,3])
C0036572 (UMLS CUI [3])